Search

The Supervisory Board of Bayer AG (BAYRY) has approved the Board of Management's recommendation that a dividend payment for fiscal 2017 of 2.80 euros per share entitled to the dividend [...]

The drug industry had a good year in 1999 and the year 2000 is also expected to be profitable, although earnings will be slightly lower. The industry is also consolidating and the debate over Medicare in the presidential campaign in the year 2000 will also have an affect on the industry. Investors need to seek those stocks with good margins and rising product lines.

Earnings and profits for the drug industry have been good for the second half of 1999 and this trend is expected to continue for the next ten years, as well, price hikes have a better environment, also. However, some drugs are losing patent protection in the coming years, and drug industry stock prices have fallen during 1999. These stocks are timely for investors due to good earnings and demographic trends in 1999 and later.

Operational basics and earnings for the pharmaceutical industry remain good for 1999 and this scenario is expected to remain in place for the near-term future. However, the stocks in this industry have declined in their timeliness rating, due in part to sector rotation into cyclical issues, despite the 19.9% increase in the Dow Jones Industrial Average since the beginning of 1999. Investors need to seek the highest quality stocks during periods of price weakness in this industry.

Stocks in the pharmaceutical industry are timely in 1999 and are expected to outperform the market with good earnings growth, revenue gains from volume and other factors. However, investment trends on Wall Street, current valuations, and economic developments in Asia and elsewhere have called the industry's bull market into question. Investors need to be cautious as this sector has compression and other risks, even though its earnings are likely to remain high for several years.

The pharmaceutical industry had good earnings in 1998 and profits were sharply higher, and this is expected to continue through 1999 although not at the previous pace. The stocks in this industry surged higher in 1998, also, with most of them beating the Standard and Poor's 500 index, as investors were seeking quality issues in this sector. The dynamics of these stocks are not attractive in 1999, however, even though investors can find some favorable issues.

The following is from Fitch Ratings on February 9: Fitch Ratings has affirmed the Long-term Issuer Default Rating (IDR), revolving credit facility (RCF) rating, and senior unsecured note ratings of [...]

Monsanto Company reported that its Board of Directors declared a quarterly dividend on its common stock of 54 cents per share. According to a media release, the dividend relates to [...]

Monsanto Company reported that its Board of Directors declared a quarterly dividend on its common stock of 54 cents per share. According to a media release, the dividend relates to [...]

Chemical industry earnings and securities are extremely volatile, highly responsive to national economic conditions and vary greatly as to performance between individual companies. Prices are expected to rise in 1996 and earnings could possibly grow but experts believe that these predictions could shift rapidly. Investors should be wary of dividend yields as they are not always indicative of chemical industry securities true value.

The basic chemical industry stands just above the median in Value Line's industry rankings. The industry is benefiting from high prices, high operating rates, added overhead and reinvestment, but will reach a cyclical peak in 1996 or early 1997. As a result, basic chemical stocks will underperform the market between 1995 and 2000 and are not recommended for conservative investors.

Monsanto Company reported that its Board of Directors declared a quarterly dividend on its common stock of 54 cents per share. According to a media release, the dividend relates to [...]

Security analysts see many chemical industry stocks as offering a high potential return for patient investors. Among their recommendations are Dow Chemical Co, Quantum Chemical Corp, Engelhard Corp, Monsanto Co, Witco Chemical Corp, Minerals Technologies Inc, IMC Fertilizer Group Inc, IMCERA Group Inc and Praxair Inc. Technological and financial developments which provide the analysts' rationale for investing in each of these companies are discussed.

Monsanto Company said that its Board of Directors declared a quarterly dividend on its common stock of 49 cents per share. According to a release, the dividend is payable on [...]

Strategic partner, fierce competitor, terrific investment, revolutionizer of crop production practices, benefactor to many agricultural causes, Monsanto means many things to many people. Still headquartered in St. Louis, MO, the [...]

The following is from Fitch Ratings on June 25: Fitch Ratings has downgraded the Long-term Issuer Default Rating (IDR), revolving credit facility rating and senior unsecured note ratings of Monsanto [...]

Fitch Ratings has affirmed the Long-term Issuer Default Rating (IDR), revolving credit facility rating, and senior unsecured note ratings of Monsanto Company (Monsanto) at 'A+'. Fitch has also affirmed Monsanto's [...]

Byline: Tom Hutchinson What a difference a couple of weeks can make. Last month the market was plummeting and this month it's on fire. Employment numbers got worse, GDP growth [...]

Byline: Tom Hutchinson What a difference a couple of weeks can make. Last month the market was plummeting and this month it's on fire. Employment numbers got worse, GDP growth [...]